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Five new organogermanium sesquioxides have been synthesized and characterized by elemental analysis and IR spectra. All the
compounds were tested for antitumor activities against KB, HCT, and Bel cells in vitro. Compound 5 (γ-thiocarbamido propyl
germanium sesquioxide) showed excellent antitumor activity, and its inhibition yield to KB, HCT, and Bel cells was 92.9%, 84.9%,
and 70.9%, respectively. A rapid method was described for the labeling compound 5 with 99mTc, and the optimum labeling
conditions were investigated. The labeling yield is above 90% in pH 7.0, 20
◦C, reaction time greater than 10 minutes, 1mg of
compound 5, and 0.075∼0.1mg of SnCl2. The biodistribution of 99mTc labeled compound 5 in nude mice bearing human colonic
xenografts was studied. The result showed that the tumor uptakes were 0.73, 0.97, 0.87, and 0.62 ID%/g at 1-hour, 3-hour, 6-hour,
and 20-hour postinjection, respectively. T/NT (the uptake ratio for per gram of tumor over normal tissues) was 18.3 for tumor
versus brain and 5.81 for tumor versus muscle at 20-hour postinjection. The tumor clearance was slow. The results showed that
compound 5 may be developed to be a suitable cancer therapeutic agent.
Copyright © 2009 Chun Li Zhang et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Germanium is a constituent of many medicine plants such as
ginseng root, and it is considered to play an important role
in the pharmacological eﬀects of the plants [1]. It is reported
that many organogermanium compounds can inhibit tumor
and metastatic growth and modify immune response by
inducing interferon-γ (IFN-γ), enhancing NK cell activ-
ity, and increasing peritoneal macrophage activity [2–5].
Besides, they are of extremely low toxicity [5, 6]. So, many
researchesfocusonsearchingforeﬀectiveandlow-toxicanti-
tumor drugs from organogermanium compounds [7–13].
Several types of organogermanium compounds have been
investigated and found to possess antitumor eﬀect [14–16],
such as tetraalkylgermanium and alkylgermanium halide
[17], spirogermanium [18], germanium sesquisulﬁde [19]
or sesquioxide [20, 21], germatranes [22], Ge-porphyrinates,
and germanium compounds containing phosphorus [23–
25], of which Ge-132 (carboxyethylgermanium sesquioxide)
has been clinically used [26, 27].
For developing more eﬀective antitumor agents from
organogermanium sesquioxides, we synthesized ﬁve new
organogermanium sesquioxides and investigated their anti-
tumor activities against KB, HCT, and Bel cells. The
compound with the highest antitumor activity was selected
for 99mTc labeling and biodistribution study in nude mice
bearing human colonic xenografts.
2. Experimental
2.1. Agents, Experimental Animals, and Instrumentation. All
commercially available chemicals were of analytical grade
and used without further puriﬁcation. 99mTcO4
− was pro-
vided by Syncor company with radiochemical purity greater
than 98%.
Experimental animals (Balb/c nude mice) were provided
by Experimental Animal Department of Chinese Academy
of Medical Sciences. The nude mice were implanted with
human colonic carcinoma cells (LoVo cells). When the2 Bioinorganic Chemistry and Applications
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Figure 1: Scheme of synthesis route.
Table 1: Inhibition yields (%) of the ﬁve compounds and Ge-132 at the concentration of 50μg/mL.
Cells Compound 1 Compound 2 Compound 3 Compound 4 Compound 5 Ge-132
K B 0000 9 2 . 9 0
HCT 0 0 0 41.5 84.9 31.4
Bel 0 0 0 0 70.9 0
tumor size was about 1cm, the mice were used for the
experiment.
IR spectra were recorded on a Bruker Equinox 55
spectrometer, US. Elemental analyses were determined on
a Yanaco CHN Corder MT-3 elemental analyzer. Mass
spectrum (MS) was detected on a Bruker APEX IV FTMS
mass spectrometer. Radioactivity was counted on a HY-901
γ counter provided by Sixin company.
2.2. Chemical Synthesis. The scheme of synthesis route is
shown in Figure 1. The details of synthetic method were
described by Niu [28].
2.2.1. Reagents.
(1) Cl3GeH. Cl3GeH was prepared by the method reported
by Bai et al. [29]. 0.01mol of GeO2, 2mL of 50% H3PO2,
and 9mL of HCl solution (11.9M) were mixed and reﬂuxed
for 4 hours. A colorless Cl3GeH solution was obtained. The
solution was extracted three times with ether to give Cl3GeH
solution in ether.
(2) β-Chloroformyl Ethyl Germanium Trichloride (I). β-
chloroformyl ethyl germanium trichloride (I) was prepared
bythemethodreportedbyBaietal.[29].0.01molpropenoicBioinorganic Chemistry and Applications 3
Table 2: Biodistribution of 99mTc labeled compound 5 in nude mice bearing human colonic cancer xenografts at various time intervals (%
ID/g, n = 3, x ±SD).
T i s s u e s 1 h3 h6 h 2 0 h
Stomach 10.10 ±3.89 5.57 ±0.89 1.27 ±0.25 0.59 ± 0.18
Small intestine 1.29 ±0.58 1.06 ±0.11 3.09 ±3.27 0.33 ± 0.14
Kidney 8.86 ±3.23 7.07 ±0.50 6.65 ±0.41 5.89 ± 0.96
Liver 2.96 ±0.99 3.65 ±0.44 2.59 ±0.07 1.99 ± 0.74
Lung 4.66 ±0.24 8.24 ±2.24 12.40 ±4.94 4.56 ± 3.28
Muscle 0.72 ±0.84 0.49 ±0.34 0.44 ±0.34 0.11 ± 0.04
Heart 0.64 ±0.23 0.58 ±0.09 0.34 ±0.00 0.21 ± 0.05
Brain 0.07 ±0.02 0.11 ±0.06 0.07 ±0.01 0.03 ± 0.01
Blood 1.26 ±0.28 0.97 ±0.18 0.55 ±0.06 0.21 ± 0.06
Tumor 0.73 ±0.10 0.97 ±0.20 0.87 ±0.04 0.62 ± 0.23
Table 3: T/NT of 99mTc labeled compound 5 at various time intervals in nude mice bearing human colonic cancer xenografts (n = 3, x±SD).
T i s s u e s 1 h3 h6 h2 0 h
Stomach 0.07 ±0.02 0.18 ±0.06 0.69 ±0.10 1.02 ±0.07
Small intestine 0.63 ±0.20 0.92 ±0.15 0.62 ±0.64 1.93 ±0.47
Kidney 0.09 ±0.04 0.14 ±0.02 0.13 ±0.02 0.10 ±0.02
Liver 0.26 ±0.06 0.27 ±0.08 0.34 ±0.03 0.31 ±0.02
Lung 0.16 ±0.02 0.12 ±0.01 0.04 ±0.01 0.27 ±0.28
Muscle 1.01 ±1.18 3.88 ±4.19 2.77 ±2.05 5.81 ±0.93
Heart 1.22 ±0.34 1.66 ±0.19 2.54 ±0.15 3.00 ±1.05
Brain 10.70 ± 3.34 9.99 ±4.53 12.90 ±2.95 18.30 ± 5.72
Blood 0.72 ±0.23 1.18 ±0.02 1.60 ±0.26 3.01 ±0.98
acid was added dropwise to 0.01mol Cl3GeH in HCl
solution. A sticky precipitate was formed. After stirring for
4 hours, the precipitate was ﬁltered and recrystallized with
CH2Cl2 to obtain 1.5g (0.0055mol) of I. 60% yield; mp:
70∼72◦C.
(3) 7-Oxabicyclo [2.2.1] Hept-5-Ene-2, 3-Dicarboxylic
Acid Anhydride (II). 7-oxabicyclo [2.2.1] hept-5-ene-2, 3-
dicarboxylic acid anhydride (II) was prepared by the method
reported by Tian et al. [30]. 0.5mol of maleic anhydride,
0.6mol of furan, and 50mL of anhydrous tetrahydrofuran
were mixed and stirred to dissolve the maleic anhydride
at 37◦C. The solution was placed in room temperature for
2∼3 days until the crystals were formed. The crystals were
ﬁltered, dried, and then recrystallized with ethanol to obtain
II. mp: 125∼127◦C.
(4) 7-Oxabicyclo [2.2.1] Hept-5-Ene-2,3-Dicarboximine (III).
7-oxabicyclo [2.2.1] hept-5-ene-2,3-dicarboximine (III) was
prepared by the method reported by Liu et al. [31]. II was
added to 25mL of ammonia liquor (14.8M) under stirring.
The mixture was reﬂuxed in boiling water for 1 hour to
yield yellow solution. The solution was cooled and stood
overnight. Needle crystals were formed. The crystals were
ﬁltered, dried, and then recrystallized with 95% ethanol to
obtain III. mp: 173∼175◦C.
(5) N-Amino-7-Oxabicyclo [2.2.1] Hept-5-Ene-2,3-Dicarbox-
imine (IV). N-amino-7-oxabicyclo [2.2.1] hept-5-ene-2,3-
dicarboximine (IV) was prepared by the method reported by
Liu et al. [31]. 5mL of 50% hydrated hydrazine was added
dropwise to 0.06mol of I in water. The mixture was reﬂuxed
in boiling water for 1 hour to yield purple solution and then
stood overnight. Lamellar crystals were formed. The crystals
were ﬁltered, dried, and then recrystallized with distilled
w a t e rt oo b t a i nI V .m p :1 4 5∼146◦C.
(6) Ethyl Glutamate (V). To prepare ethyl glutamate (V), a
mixture of glutamic acid (0.2mol) and anhydrous ethanol
(100mL) was reﬂuxed in an oil bath. Dry hydrochloride gas
was ventilated until the amino acid was dissolved completely.
Then we stopped heating and continued to stir the reaction
mixture for 1 hour. Evaporation of the excess ethanol in
vacuo resulted in light yellow oil. 40mL of distilled water
was added, and the pH of the solution was increased by the
additionof8gofNaOHandstirredfor2hours.Thereaction
mixture was extracted three times with ethyl acetate (15mL),
dried (with anhydrous Na2SO4), and concentrated in vacuo
to give V as a light yellow oil.
2.2.2. Synthesis of Germanium Sesquioxides of 7-Oxabicyclo
[2.2.1] Hept-2,3-Dicarboxylic Acid Anhydride, and 7-
Oxabicyclo [2.2.1] Hept-2,3-Dicarboximine Derivatives
(Compound 1, 2, 3). To a solution of II or III, IV (0.01mol)
in an anhydrous solvent was added dropwise Cl3GeH4 Bioinorganic Chemistry and Applications
(0.01mol), and the solution was stirred overnight. The
solvent was evaporated in vacuo, and the residue was
dissolved in distilled water (20mL) and stirred for 2∼3
hours to give a hydrolyzed product as a precipitate. The
precipitate was ﬁltered, washed with aforementioned solvent
and distilled water, and dried to aﬀord compound 1 or 2, 3.
Compound 1:
1607 (               ). 817, 880 (                        ). C O Ge
O
O
O
Ge C 499 (                ).
68.2% yield; d.t 264~265°C; IR (KBr,   cm   ): -1 ν
Elementalanalysis:C:36.21%,H:2.62%(found);C:36.42%,
H: 2.66% (calcd.).
Compound 2:
1772, 1708 (               ). 822, 895 (                        ). C O Ge
O
O
O
Ge C 522 (                ). 3417 (           ).
40.7% yield; d.t 295-298°C; IR (KBr,   cm   ): -1
NH
ν
Elemental analysis: C: 36.38%, H: 3.00%, N: 5.29% (found);
C: 36.56%, H: 3.05%, N: 5.33% (calcd.).
Compound 3:
1781, 1710 (               ). 828, 888 (                        ). C O Ge
O
O
O
Ge C 561 (                ). 3418 (           ).
36.1% yield; d.t >300°C; IR (KBr,   cm   ): -1
NH
ν
Elementalanalysis:C:34.63%,H:3.29%,N:10.01%(found);
C: 34.58%, H: 3.24%, N: 10.09% (calcd.).
Compound 4:
1650, 1736 (               ). 802, 898 (                        ). C O Ge
O
O
O
Ge C 567 (                ). 3313 (           ).
37.2% yield; d.t 212-214°C; IR (KBr,   cm   ): -1
NH
ν
Elemental analysis: C: 41.02%, H: 5.64%, N: 4.01% (found);
C: 40.61%, H: 5.64%, N: 3.95% (calcd.).
Compound 5:
1636 (               ). 814 (                        ). C O Ge
O
O
O
NH Ge C 547 (                ). 3301 (           ).
63.2% yield; d.t 195-198°C; IR (KBr,   cm   ): -1 ν
Elementalanalysis:C:21.96%,H:4.23%,N:13.09%(found);
C: 22.47%, H: 4.21%, N: 13.11% (calcd.).
2.2.3. Synthesis of Germanium Sesquioxide of Ethyl Glutamate
(Compound 4). To a vigorously stirred solution of I in ether
(10mL) was added dropwise a solution of V (4.0g) in
ether, and the solution was stirred for 6 hours. A white
sticky precipitate was formed and ﬁltered oﬀ. The ﬁltrate
was evaporated in vacuo to remove ether. Adding 10mL of
distilled water and stirring for 6∼7h o u r sy i e l d e daw h i t e
precipitate. The precipitate was ﬁltered, washed three times
with distilled water, and dried to give compound 4 as a white
or light yellow powder.
2.2.4. Synthesis of γ-Thiocarbamido Propyl Germanium
Sesquioxide (Compound 5). To a solution of propenyl thio-
carbamide (0.01mol) in anhydrous ethynol was added
dropwise a solution of Cl3GeH (0.01mol) in ether, and
the solution was stirred for 3∼4 hours. The solvent was
evaporated in vacuo to give an oily residue. Addition of
distilled water (20mL) yielded a bright yellow precipitate.
The solution was kept stirring for 2 hours. The precipitate
was ﬁltered, washed three times with distilled water, and
dried to give compound 5.
2.3. Antitumor Activity. The antitumor activity in vitro
was assayed by the MTT method [32] using DMSO as
solvent. The tumor inhibition yield and IC50 of the ﬁve
organogermanium sesquioxides and Ge-132 against KB
(human nasopharyngeal cancer), HCT (human colonic
cancer), and Bel (human liver cancer) cells were measured.
2.4. Radiolabeling with 99mTc. Since compound 5 showed
best antitumor activity, it was selected for further radiolabel-
ingandbiodistributionstudies.Tothesolutionofcompound
5 in NaOH solution (2mol/L), 100μL freshly prepared
SnCl2·H2O solution was added, and pH was adjusted to
the required value. 3700∼5500kBq of 99mTcO4
− eluate was
added, and the solution was stirred for 5∼25 minutes to give
the labeled compound. Labeling yield was measured by TLC
with polyamide membrane in the solvent of (CH3)2CHOH :
NH4OH : H2O = 15 : 13 : 5 (v/v/v). Rf: labeled
compound: 0.3∼0.4, 99mTcO4
−:0 . 5 ∼0.6, 99mTcO·xH2O:
0∼0.1. Reaction conditions were optimized by varying
the concentration of germanium sesquioxide solution and
reducing agent (SnCl2), pH, temperature, and reaction time.
2.5. Biodistribution. Twelve nude mice bearing human
colonic cancer xenografts were injected in tail vein with
555∼740kBq of 99mTc labeled compound 5. Three animals
were sacriﬁed at 1-hour, 3-hour, 6-hour, and 20-hour
postinjection, respectively. Tissues and organs were excised,
rinsed, weighted, and counted in a γ counter. The uptake
percentage of the injected dose per gram of the measured
organ(ID%/g)andtheratioofID%/goftumorovernormal
tissues (T/NT) were calculated.
3. Results
3.1. Preparations. The compounds were prepared under
mild condition. All the ﬁve compounds are powder and
stable under ordinary conditions. They all are not soluble inBioinorganic Chemistry and Applications 5
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Figure 2: Labeling yields (Lys) at diﬀerent conditions.
water, alcohol, slightly soluble in DMSO, but compounds 3,
4, and 5 are easily soluble in 2mol/L of NaOH solution.
The elemental analysis data and IR spectra were con-
sistent with the expected structure of the compounds. In
IR spectra, the wide absorption band at 800∼900cm−1
corresponds to the characteristic region of νGe–O. The
weak absorption peak at about 550cm−1 corresponds to the
characteristic region of νGe–C.
MS was performed on compound 5 dissolved in the
mixture of DMSO and methanol. The solvent was selected
because DMSO was the solvent for measuring antitumor
activity, and methanol was used to decrease the viscosity
of the solution to facilitate MS detection. MS showed the
compound containing two germanium atoms with m/z
456.815. The m/z value corresponds to the molecular weight
of the formula [Ge(CH2)3NHCSNHCH3]2O3 which may
be formed by methylation of [Ge(CH2)3NHCSNH2]2O3 by
methanol in DMSO.
3.2. Antitumor Activity. The antitumor activities of the ﬁve
compounds and Ge-132 at the concentration of 1, 10, and6 Bioinorganic Chemistry and Applications
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Figure 3: ID %/g of compound 5 in tumor, muscle, and blood at
diﬀerent time points.
50μg/mL were tested. All the ﬁve compounds showed no
antitumor activity at the concentration of 1 and 10μg/mL.
The antitumor activities of the compounds at the concentra-
tion of 50μg/mL are listed in Table 1. The results of bioassay
show that compounds 4, 5 exhibit certain activities against
cancer cells, but compounds 1, 2, 3 show no antitumor
activity. Compound 5 shows the highest antitumor activity.
Its inhibition yields to KB, HCT, and Bel cells are 92.9%,
84.9%, and 70.9%, respectively. IC50 is smaller than 10−7 M
(IC50 < 10−7 M is considered as strong inhibition, IC50 =
10−7 ∼ 10−6 M as medium inhibition, and IC50 = 10−6 ∼
10−5 Masweakinhibition).Ge-132showsantitumoractivity
in vitro only to HCT cell, and the inhibition yield is 31.4%.
3.3. 99mTc Labeling. Labeling yields of compound 5 at
diﬀerent conditions are showed in Figure 2.T h ec o m p o u n d
shows maximum labeling yield of above 90% at 1mg of
the germanium sesquioxide, pH 7.0∼8.0, 20◦C, with 0.075∼
0.1mg of SnCl2 as reducing agent for more than 10 minutes
of reaction.
3.4. Biodistribution. The result of the biodistribution study
o fc o m p o u n d5i nn u d em i c ei st a b u l a t e di nTable 2.T h e
uptakesofthecompoundinheart,brain,andmusclearelow.
It shows high uptake in liver, kidney, and lung. The lung has
the highest uptake at 3-hour and 6-hour postinjection.
Tumor uptakes of compound 5 are 0.73, 0.97, 0.87,
and 0.62 ID %/g at 1-hour, 3-hour, 6-hour, and 20-hour
postinjection, respectively, which are higher than those of
muscle, heart, and brain but lower than those of kidney,
liver, and lung. The clearance of the compound in tumor
is relatively low (Figure 3). At 20-hour postinjection, the
tumor uptake is higher than that of all other tissues except
kidney, liver, and lung. The maximum T/NT is the ratio
of tumor to brain (18.30) and followed by the ratio of
tumor to muscle (5.81) at 20-hour postinjection. T/NT for
tumor versus blood increases with time with the maximum
of 3.01 at 20-hour postinjection (Table 3). The result of its
relatively high tumor uptake and low tumor clearance as well
as its high tumor inhibition yield suggests that compound
5 may be developed to be a suitable agent for cancer
therapy.
4. Discussion
Mironov et al. synthesized bis (2-carboxyethylgermanium)
sesquioxide (now known as Ge-132) in the 1960s [33]. In the
1970s, Japanese scholar K. Asai. synthesized organogerma-
nium pharmaceuticals with wide spectra of pharmacological
activities, in which he found Ge-132 showing antitumor
activity [34]. Since then, a lot of studies showed that
many organogermanium compounds can modify immune
function, inhibit tumor cell proliferation [35], induce tumor
cell apoptosis [36], and they are eﬃcient in treating
and preventing cancers [37–40]. Besides, they can also
relieve cancer-induced pain [41], but the main problem of
organogermanium compounds used as antitumor agents is
their low pharmacological eﬀects, which makes them can
only be used as auxiliary agents in tumor therapy. So,
development of more eﬀective antitumor organogermanium
compounds is a valuable subject.
In this study, ﬁve new organogermanium compounds
were synthesized and characterized by elemental analysis
data and IR spectra. The elemental analysis data and IR
spectra were consistent with the expected structure of the
compounds.InIRspectra,thewideabsorptionbandat800∼
900cm−1 of the characteristic region of νGe–O provides
support for Ge–O network structure. The weak absorption
peak at about 550cm−1 corresponds to the characteristic
region of νGe–C. The result shows that Ge–O network
structure and Ge–C bond exist in the compounds.
One of the characteristics of germanium compounds
is polymorphism [5] .T h eb a s i cf o r m u l ao fg e r m a n i u m
sesquioxidesis(GeR)2O3.Sogermaniumsesquioxidescanbe
represented by [(GeR)2O3]n where R is the group conjugated
withgermaniumatomandn is the degree of polymerization.
The degree of polymerization strongly inﬂuences the toxicity
of the compounds. It is reported that the value of “n”
depends on the way in which a solid product separates
out of a solution of the compound. Particle size and bulk
density of the dried solid in batch-to-batch comparisons
are notoriously variable. Although there may be many
polymorphic solid forms, the aqueous solutions, once they
are formed, are identical [5]. In this study, the “n”v a l u eo f
compound 5 in the mixture of DMSO and methanol was
detected. The result showed that the compound existed in
dimer form in the solution.
Two of the ﬁve compounds showed certain antitumor
activity at the concentration of 50μg/mL. Compound 5
showed very high antitumor activity with the inhibition
yields of 92.9%, 84.9%, and 70.9% to KB, HCT, and Bel cells
at the concentration of 50μg/mL (0.117mmol/L), respec-
tively. Compound 4 showed antitumor activity only to HCT
cell with the inhibition yield of 41.5%. The antitumor activi-
tiesofcompound4andcompound5werehigherthanthatof
Ge-132whichhasbeenclinicallyused.ButGe-132showedits
in vivo antitumor eﬀect partly due to its inducing the antitu-
mor immunity of the host. Whether the new organogerma-Bioinorganic Chemistry and Applications 7
nium compounds synthesized have the in vivo immunopo-
tentiating activity needs to be further investigated.
Since many organogermanium compounds have
radiosensitive eﬀect [36], it is expected that radiolabeled
organogermanium compounds may be more eﬀective in the
therapy of cancer by synergic eﬀect of cytotoxicity of the
compoundsandradiationeﬀect.Weinvestigatedthemethod
of labeling compound 5 with 99mTc. The result showed that
the compound can be successfully labeled with labeling
eﬃciency greater than 90%. The therapeutic radionuclide,
186Re or 188Re, has similar chemical property to 99mTc. So it
is hopeful to label the organogermanium compound with
186Re or 188Re for the tumor therapy study. This work will be
done later.
Labeling compound 5 with 99mTc also allowed the
biodistribution study of the compound in nude mice bearing
human colonic cancer. The biodistribution data showed that
the compound was mainly concentrated in kidney, lung, and
next in liver. Tumor uptake was higher than that of muscle,
heart,andbrain,butlowerthanthatofkidney,liver,andlung
after 3-hour postinjection. The clearance of the compound
in tumor was relatively low. The result showed that the com-
pound has relative high tumor uptake and low tumor clear-
ance,whichfacilitatesusingthecompoundincancertherapy.
5. Conclusion
A new class of organogermanium sesquioxides was syn-
thesized and characterized. The antitumor activity, 99mTc
labeling, and biodistribution were studied. Of the ﬁve
compounds,compound5showsexcellentantitumoractivity,
high tumor uptake, and slow clearance in tumor. It may be
developed to be a suitable cancer therapeutic agent. The in
vivoantitumoreﬀects of the organogermanium sesquioxides
need to be further investigated.
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